Gilead rejigs HIV immunotherapy pact, grabs a stake in biotech partner
Back in November, immunotherapy player Hookipa told investors about a twist in its big collaboration with Gilead: The biotech giant decided not to move forward with an HIV program “according to current terms,” sparking discussions about a new, revised pact.
Almost four months later, the companies have reached a deal.
Gilead, which had agreed to foot the R&D bill for a joint research phase under the original terms drafted in 2018, now wants Hookipa to use “commercially reasonably efforts to further develop its HIV program candidate” through the completion of a Phase Ib clinical trial. Once they reach that point, Gilead has the exclusive right to take back the development rights.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.